What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide and nicardipine
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names nicardipine in its drug interactions section; the nicardipine labels PlainMeds reads (2) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “Caution is warranted and clinical monitoring is recommended upon coadministration of calcium channel blockers with GENVOYA.”
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the nicardipine FDA label on DailyMed (effective August 24, 2024, Hikma Pharmaceuticals USA Inc.).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about nicardipine?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ calcium channel blockers; Clinical Comment: Caution is warranted and clinical monitoring is recommended upon coadministration of calcium channel blockers with GENVOYA.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What does the nicardipine label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Nicardipine's label (effective August 24, 2024) and its 1 other brand-application label do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nicardipine Hydrochloride), Hikma Pharmaceuticals USA Inc., effective August 24, 2024 (SPL set 18fb1c2b-0c1e-436c-a5b6-d4840b5da228), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Nicardipine | |
|---|---|---|
| Labeled for | HIV | High blood pressure, Angina |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $143.35 per tablet Genvoya tablet | $1.12 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once